Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (9989) convened a board meeting on November 24, 2025. The meeting approved resolutions to abolish the Supervisory Committee, transfer its functions to the Audit Committee of the board, and amend the company’s Articles of Association, related procedural rules, and certain internal governance measures. These proposals will be submitted for shareholder approval by special resolution at the forthcoming extraordinary general meeting (EGM).

Meanwhile, the board noted that the term of office for independent non-executive director Dr. Lu Chuan will expire in December 2025 after almost six consecutive years of service. He will step down effective December 16, 2025. The board expressed its appreciation for Dr. Lu’s contributions and proposed to elect Mr. Pu Hong, who has extensive experience in corporate restructuring, mergers and acquisitions, and initial public offerings, as the new independent non-executive director. Shareholders will vote on Mr. Pu’s election and remuneration plan at the upcoming EGM.

A circular outlining the details of these proposals and a notice of the EGM will be dispatched to shareholders in due course.